55097
Glycine hydrochloride solution
100 mM amino acid in 0.1 M HCl, analytical standard
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
보기 변경
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C2H5NO2 · HCl
CAS 번호:
Molecular Weight:
111.53
NACRES:
NA.24
PubChem Substance ID:
eCl@ss:
32160406
UNSPSC Code:
85151701
MDL number:
Beilstein/REAXYS Number:
3909617
grade
analytical standard
Quality Level
assay
≥99.5%
form
liquid
analyte chemical class(es)
amino acids, peptides, proteins
concentration
100 mM amino acid in 0.1 M HCl
technique(s)
HPLC: suitable, gas chromatography (GC): suitable
color
colorless
application(s)
food and beverages
format
single component solution
storage temp.
2-8°C
SMILES string
Cl.NCC(O)=O
InChI
1S/C2H5NO2.ClH/c3-1-2(4)5;/h1,3H2,(H,4,5);1H
InChI key
IVLXQGJVBGMLRR-UHFFFAOYSA-N
Application
Glycine hydrochloride in combination with 1-allyl-3-methylimidazolium chloride can find applications as an ionic liquid solvent, which can be used to dissolve chitosan and also fabricate chitosan/cellulose blend films with definite proportions of chitosan. It can also be used to treat the condition of achlorhydria.
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Met. Corr. 1 - Skin Irrit. 2
flash_point_f
Not applicable
flash_point_c
Not applicable
저장 등급
12 - Non Combustible Liquids
Jr, M.J.J.
Encyclopedia of Chemical Processing and Design (1977)
Antibacterial blend films of cellulose and chitosan prepared from binary ionic liquid system
Fu R, et al.
Fibers and Polymers, 18, 852-858 (2017)
Emilie Macé et al.
Molecular therapy : the journal of the American Society of Gene Therapy, 23(1), 7-16 (2014-08-07)
Most inherited retinal dystrophies display progressive photoreceptor cell degeneration leading to severe visual impairment. Optogenetic reactivation of retinal neurons mediated by adeno-associated virus (AAV) gene therapy has the potential to restore vision regardless of patient-specific mutations. The challenge for clinical